Home › Marginal Zone Lymphoma › Minnesota › Minneapolis
Marginal Zone Lymphoma clinical trials in Minneapolis, MN
4 studies for Marginal Zone Lymphoma are looking for participants at sites in and around Minneapolis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RecruitingPhase 2
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi away
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RecruitingPhase 2
- Masonic Cancer Center, Minneapolis
Allo HSCT Using RIC and PTCy for Hematological Diseases
RecruitingPhase 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RecruitingPhase 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Marginal Zone Lymphoma trials in other cities
- Durham, NC12 studies
- New York City, NY11 studies
- Seattle, WA9 studies
- Milwaukee, WI9 studies
- Boston, MA9 studies
- Baldwin Park, CA9 studies
- Rochester, MN8 studies
- Edison, NJ8 studies
- Columbus, OH8 studies
- Houston, TX8 studies
- Miami, FL7 studies
- Denver, CO7 studies
Other studies in Minneapolis
- Breast Cancer27 studies
- Non-Small Cell Lung Cancer26 studies
- Ovarian Cancer24 studies
- Prostate Cancer23 studies
- Cancer (all types)22 studies
- Heart Failure21 studies
- Lung Cancer20 studies
- Acute Myeloid Leukemia20 studies
- Colorectal Cancer19 studies
- Endometrial Cancer18 studies
- Parkinson's Disease17 studies
- Cardiovascular Disease15 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.